

# CITATION REPORT

List of articles citing

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

DOI: 10.1186/s12933-016-0356-y  
Cardiovascular Diabetology, 2016, 15, 37.

**Source:** <https://exaly.com/paper-pdf/65254452/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
140	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <b>2016</b> , 11, e0166125		126
139	An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. <b>2017</b> , 24, 73-79		117
138	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. <b>2016</b> , 18, 766-74		19
137	Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. <b>2016</b> , 33, 511-22		21
136	Quantitative Systems Pharmacology: Applications and Adoption in Drug Development. <b>2016</b> , 27-52		3
135	Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. <b>2016</b> , 5, e84		15
134	New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. <b>2016</b> , 69, 1088-1097		1
133	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. <b>2016</b> , 26, 1071-1078		12
132	Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. <b>2016</b> , 18, 1034-40		29
131	Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. <b>2016</b> , 69, 1088-1097		6
130	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <b>2016</b> , 32, 1513-4		13
129	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. <b>2016</b> , 128, 398-408		2
128	Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. <b>2016</b> , 128, 346-55		31
127	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. <b>2017</b> , 40, 535-540		24
126	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 18	8.7	34
125	SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. <b>2017</b> , 10, 429-442		13
124	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. <b>2017</b> , 11, 450-458.e1		21

123	Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. <b>2017</b> , 25, 262-284		552
122	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <b>2017</b> , 88, 249-253		30
121	Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 8	8.7	76
120	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 29	8.7	63
119	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. <b>2017</b> , 18, 517-527		4
118	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. <b>2017</b> , 31, 1215-1221		25
117	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <b>2017</b> , 19, 1353-1362		88
116	SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 65	8.7	50
115	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <b>2017</b> , 43, 299-313		16
114	Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. <b>2017</b> , 39, 1244-1264		9
113	SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. <b>2017</b> , 129, 409-420		25
112	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. <b>2017</b> , 13, 583-592		7
111	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. <b>2017</b> , 19, 1276-1288		37
110	Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. <b>2017</b> , 11, 590-596		4
109	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. <b>2017</b> , 12, 751-759		89
108	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. <b>2017</b> , 10, 1303-1316		4
107	Pharmacological management of type 2 diabetes: what's new in 2017?. <b>2017</b> , 10, 1383-1394		16
106	Budes LEADER et EMPA-REG OUTCOME : implications en pratique clinique. <b>2017</b> , 11, 2S49-2S55		

105	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <b>2017</b> , 5, 709-717		208
104	Durability of response to dapagliflozin: a review of long-term efficacy and safety. <b>2017</b> , 33, 1685-1696		9
103	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <b>2017</b> , 18, 1243-1260		30
102	Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. <b>2017</b> , 31, 494-503		14
101	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <b>2017</b> , 13, 69-79		6
100	Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. <b>2017</b> , 9, e1751		4
99	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. <b>2017</b> , 2017, 9257930		0
98	Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. <b>2017</b> , 10, 317-332		7
97	The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. <b>2017</b> , 18,		44
96	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). <b>2017</b> , 13, 1569-1576		3
95	Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 84	8.7	134
94	Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 93	8.7	21
93	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 137	8.7	9
92	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. <b>2018</b> , 23, 303-323		27
91	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. <b>2018</b> , 130, 381-393		17
90	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. <b>2018</b> , 26, 312-320		4
89	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <b>2018</b> , 200, 83-89		89
88	Management of diabetes in older adults. <b>2018</b> , 28, 206-218		30

87	Type 2 diabetes: glycaemic control. <b>2018</b> , 241-313		
86	DECLARE-TIMI 58: ParticipantsSbaseline characteristics. <b>2018</b> , 20, 1102-1110		80
85	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <b>2018</b> , 34, e2981		12
84	Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects. <b>2018</b> , 31, 274-280		3
83	SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. <b>2018</b> , 20, 1977-1982		39
82	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). <b>2018</b> , 20, 895-896		13
81	Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors. <b>2018</b> , 28, 1182-1187		17
80	SGLT2 inhibitors: are they safe?. <b>2018</b> , 130, 72-82		36
79	Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. <b>2018</b> , 114, 336-346		78
78	Pharmacotherapy of type 2 diabetes: An update. <b>2018</b> , 78, 13-42		103
77	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. <b>2018</b> , 20, 344-351		124
76	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. <b>2018</b> , 14, 1273-1285		4
75	A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 144	8.7	57
74	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <b>2018</b> , 70, 915-921		3
73	Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes. <b>2018</b> , 8, 14872		26
72	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. <b>2018</b> , 72, 1845-1855		121
71	The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. <b>2018</b> , 17, 815-824		10
70	Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 79	8.7	20

69	The effect of dapagliflozin treatment on epicardial adipose tissue volume. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 6	8.7	147
68	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. <b>2018</b> , 122, 1439-1459		148
67	The treatment of type 2 diabetes in heart failure. <b>2018</b> , 35, 123-126		2
66	Studies towards the synthesis of ertugliflozin from l-Arabinose. <b>2018</b> , 74, 5700-5708		5
65	Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. <b>2018</b> , 234, 223-230		49
64	Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk. <b>2019</b> , 13, 2549-2556		11
63	Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). <b>2019</b> , 21, 415-422		4
62	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <b>2019</b> , 40, 1447-1467		85
61	Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 393-428	3.6	10
60	Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> , <b>2019</b> , 79, 1135-1146	12.1	37
59	Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. <b>2019</b> , 14, 100099		
58	Synthesis of ertugliflozin from d-glucose. <b>2019</b> , 60, 994-996		4
57	Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 891-899	3.6	10
56	Therapie des Typ-2-Diabetes. <b>2019</b> , 15, 146-167		3
55	Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. <b>2019</b> , 60, 629		7
54	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <b>2019</b> , 12, 2549-2557		4
53	Heart Failure in Type 2 Diabetes Mellitus. <b>2019</b> , 124, 121-141		210
52	The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes. <b>2019</b> , 42, 406-412		6

51	A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. <b>2019</b> , 12, 45-52		3
50	Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. <b>2020</b> , 35, 1570-1576		9
49	Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. <b>2020</b> , 22, 373-382		12
48	Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications: An overview. <b>2020</b> , 67, 920-928		9
47	Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial. <b>2020</b> , 99, e22660		
46	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. <b>2020</b> , 28, 219-235		4
45	Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. <b>2020</b> , 16, 556-577		67
44	Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 87	8.7	15
43	Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions. <b>2020</b> , 127, 134-141		4
42	Pivaloyl-protected glucosyl iodide as a glucosyl donor for the preparation of EC-glucosides. <b>2020</b> , 61, 152173		0
41	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <b>2020</b> , 83, 587-621		3
40	Diabetes and Heart Failure: A Marriage of Inconvenience. <i>Clinics in Geriatric Medicine</i> , <b>2020</b> , 36, 447-455	3.8	2
39	Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED). <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvz017	0.4	19
38	Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1307, 213-230	3.6	6
37	Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. <i>Oman Medical Journal</i> , <b>2021</b> , 36, e273	1.4	2
36	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , <b>2021</b> , 6-61	0.7	2
35	Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 139	8.7	2
34	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , <b>2021</b> , 81, 1491-1511	12.1	6



33	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 487-498	3.3	1
32	Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2076, 1-30	1.4	5
31	TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?. <i>Russian Journal of Cardiology</i> , <b>2018</b> , 79-91	1.3	5
30	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , <b>2020</b> , 25, 4083	1.3	95
29	The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. <i>European Endocrinology</i> , <b>2018</b> , 14, 17-23	3.4	21
28	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 515-537	3.3	12
27	SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. <i>Current Diabetes Reviews</i> , <b>2019</b> , 15, 349-356	2.7	3
26	The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2019</b> , 19, 207-213	2.2	2
25	Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2019</b> , 23, 140-149	1.7	5
24	Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2019</b> , 23, 150-158	1.7	1
23	Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. <i>World Journal of Diabetes</i> , <b>2018</b> , 9, 252-257	4.7	13
22	Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. <i>International Journal of Endocrinology and Metabolism</i> , <b>2019</b> , 17, e84353	1.8	18
21	Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. <i>Drugs in Context</i> , <b>2016</b> , 5, 212299	5.2	2
20	Antidiabetic drugs of interest. <i>Interni Medicina Pro Praxi</i> , <b>2016</b> , 18, 125-129	0	
19	Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2017</b> , 21, 618-629	1.7	2
18	Comments on current guidelines of type 2 diabetes mellitus treatment. <i>Vnitřní Lekarství</i> , <b>2017</b> , 63, 211-213	1.3	1
17	ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE. <i>Meditsinskiy Sovet</i> , <b>2017</b> , 22-30	0.4	2
16	Meta-Analysis on Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus. <i>Yangtze Medicine</i> , <b>2018</b> , 02, 129-145	0.1	



15	Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism. <i>Journal of Lipid and Atherosclerosis</i> , <b>2018</b> , 7, 21	3
14	[Analysis of cardiovascular safety of novel glucose-lowering medications]. <i>Kardiologiya</i> , <b>2019</b> , 59, 76-83	1.5
13	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). <i>Eurasian Heart Journal</i> , <b>2020</b> , 6-76	0.7 3
12	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. <i>Metabolites</i> , <b>2021</b> , 11,	5.6
11	[Dapagliflozin in the prevention and treatment of heart failure]. <i>Semergen</i> , <b>2021</b> , 47 Suppl 1, 11-17	1.9
10	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5 9
9	Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.. <i>Diabetology and Metabolic Syndrome</i> , <b>2022</b> , 14, 41	5.6 0
8	Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance -What are the medical treatments to prevent cardiovascular events in such patients?. <i>Journal of Diabetes Investigation</i> , <b>2022</b> ,	3.9 0
7	Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?. <i>European Medical Journal (Chelmsford, England)</i> ,	7.5
6	Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy. <i>Diabetes Therapy</i> ,	3.6 0
5	Cardio-Onco-Metabolism [Metabolic vulnerabilities in cancer and the heart. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2022</b> ,	5.8
4	Epicardial adipose tissue and right ventricular function in type 2 diabetes mellitus using two-dimensional speckle tracking echocardiography. <b>2022</b> , 19, 147916412211186	
3	Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. <b>2022</b> , 10, 2133	0
2	Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series. <b>2022</b> , 11, 465-473	0
1	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. 14,	0